Company Overview - Gyre Therapeutics is a biopharmaceutical company based in San Diego, CA, focused on developing and commercializing Hydronidone for liver fibrosis, including MASH, in the United States [3] - The company leverages its experience in mechanistic studies using MASH rodent models and clinical studies in CHB-induced liver fibrosis [3] - In China, Gyre is advancing a broad pipeline through its indirect controlling interest in Gyre Pharmaceuticals, which includes therapeutic expansions of ETUARY and development programs for F573, F528, and F230 [3] Upcoming Events - Management will present at the H.C. Wainwright 27 Annual Global Investment Conference on September 10, 2025, at 12:30 p.m. ET [1] - A live webcast of the presentation will be available on Gyre's website, with a replay accessible after the live session [2]
Gyre Therapeutics to Present at the H.C. Wainwright 27th Annual Global Investment Conference